| Autor: |
Ali, Wajahat, Nasir, Shua, Shahbaz, Lal, Aqil, Mohammed, Asim, Syed Jehanzeb, Samad, Abdul |
| Předmět: |
|
| Zdroj: |
Pakistan Journal of Surgery; Jul-Sep2021, Vol. 37 Issue 3, p196-199, 4p |
| Abstrakt: |
Background: Acute asthma management is based on rapid reversal of bronchospasm and reduced inflammatory mucosa of airway. The age old solution i.e. nebulization with β agonist therapy, is increasingly being with discouraging results in moderate to severe asthmatics. Since the "poor responders" comprise up to 30% of all acute asthmatics, the need for newer options is real. Objective: To study the therapeutic efficacy of magnesium sulphate (intravenous) for the treatment of acute asthma in the emergency department. Material and Methods: Sample of 100 patients taken for this study from 1st January 2020 till 31st December 2020. with acute exacerbation of asthma, this is a prospective cohort study. No any bias was noticed related to gender or age.and the sample was collected using non-probability, consecutive sampling. Simple clinical assessment was done for the entire sample and oxygen saturation along with peak expiratory flow rate before and after the intervention were recorded in addition to basic biodata and socio-demographic details and disease particulars. The patients were randomly designated into two groups-A (Intravenous placebo infusion of normal saline) and B (Intravenous infusion of 1.2g magnesium sulphate) after conventional β agonist therapy failed to produce significant improvement in peak expiratory flow rate. The data was recorded in proforma and analyzed using SPSS v.21. & MicrosoftExcel. Results: 112-patients were enrolled, in this study males were 63.4% & 36.6% were females. The mean age is 44 years (SD ± 13.11) and most (33.03%) of the patient were aged 56 and above. The group was taking treatment reveals an elevation in peak expiratory flow rate from 212 to 293 L/min in comparison with 202 to 219 L/min in the placebo group. In addition, The ratio was significantly improved in treatment group in comparison with placebo group in admitt ed vs discharged. Conclusion: After careful consideration, it can be concluded that the intravenous magnesiumsulfate has high therapeutic efficacy when used in for acute episodes of moderate to severe asthma in patients that respond poorly to conventional nebulized β-agonist therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
